NEW YORK — GNA Biosolutions said on Tuesday that its Octea SARS-CoV-2 batch testing system has received Emergency Use Authorization from the German Federal Institute for Drugs and Medical Devices.
The system is based on a proprietary PCR technology, called pulsed control amplification, that uses short electrical pulses to drive rapid amplification cycles and can amplify nucleic acids directly from samples without additional preparation.